- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06669598
ENHANCING PHYSICAL and COGNITIVE EFFICIENCY in INDIVIDUALS AT RISK of DEMENTIA USING WHOLE-BODY ELECTROMYOSTIMULATION
October 30, 2024 updated by: Giuseppe Calcagno, University of Molise
ENHANCING PHYSICAL and COGNITIVE EFFICIENCY in ELDERLY INDIVIDUALS AT RISK of DEMENTIA USING WHOLE-BODY ELECTROMYOSTIMULATION
This study aimed to evaluate the effectiveness of twelve weeks whole-body electrical muscle stimulation combined with aerobic exercises.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study aimed to evaluate the effectiveness of twelve weeks of WB-EMS (whole-body electrical muscle stimulation at 35Hz and 350 μs) combined with aerobic exercises on a treadmill and rowing machine, in improving physical and cognitive performance in older adults, both healthy and at risk of dementia.
The results were compared with those obtained from the same training without WB-EMS.
Study Type
Interventional
Enrollment (Actual)
61
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
CB
-
Campobasso, CB, Italy, 86100
- Università degli studi del molise
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- age from 55 to 85 years;
- no simultaneous participation in any type of supervised physical activity;
- Sedentary lifestyle
Exclusion Criteria:
- mini-mental state examination (MMSE) score of less than 24;
- inability to walk for 6 min without assistance;
- the presence of a medical condition influencing the cognitive and/or motor functions;
- the presence of any counter indication for the utilisation of EMS, such as cardiovascular diseases, stents, cardiac pacemakers, and diabetes mellitus, verified by medical certification.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental Training Group
The ETG group underwent in two 20-minute training sessions per week, with 72 hours of rest between sessions.
Each session included aerobic activities such as rowing and treadmill exercises, combined with supervised WB-EMS stimulation.
This stimulation utilised a rectangular waveform at 35 Hz, 350 μs, with continuous pulse duration.
The intensity of this training modality was set based on heart rate reserve (HRR), starting at 60% HRR in the first week and increasing by 5% every 3 weeks, reaching 80% HRR by the twelfth week.
|
The ETG group underwent in two 20-minute training sessions per week (12 weeks), with 72 hours of rest between sessions.
Each session included aerobic activities such as rowing and treadmill exercises, combined with supervised WB-EMS stimulation.
This stimu-lation utilised a rectangular waveform at 35 Hz, 350 μs, with continuous pulse dura-tion
|
|
Active Comparator: Control group
The CON group underwent three weekly training sessions for twelve weeks, con-sisting of 20 minutes of aerobic activity, performed on a treadmill and rowing machine, without the WB-EMS superimposition.
|
The CON group underwent three weekly training sessions for twelve weeks, con-sisting of 20 minutes of aerobic activity, performed on a treadmill and rowing machine, without the WB-EMS superimposition.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
30-second arm curl test
Time Frame: At the end of 12 weeks
|
At the end of 12 weeks
|
|
30-second sit-to-stand test
Time Frame: At the end of 12 weeks
|
At the end of 12 weeks
|
|
hand grip strength test
Time Frame: At the end of 12 weeks
|
At the end of 12 weeks
|
|
6-minute walking test
Time Frame: At the end of 12 weeks
|
At the end of 12 weeks
|
|
8-foot up and go test
Time Frame: At the end of 12 weeks
|
At the end of 12 weeks
|
|
Chair Sit and Reach Test
Time Frame: At the end of 12 weeks
|
At the end of 12 weeks
|
|
Soda Pop Test
Time Frame: At the end of 12 weeks
|
At the end of 12 weeks
|
|
Tinetti Balance and Gait Test
Time Frame: At the end of 12 weeks
|
At the end of 12 weeks
|
|
Mini-Mental State Examination (MMSE)
Time Frame: At the end of 12 weeks
|
At the end of 12 weeks
|
|
Rey's Auditory Verbal Learning Test (RAVLT)
Time Frame: At the end of 12 weeks
|
At the end of 12 weeks
|
|
Stroop Colour and Word Interference Test (SCWT)
Time Frame: At the end of 12 weeks
|
At the end of 12 weeks
|
|
Trail Making Test (TMT)
Time Frame: At the end of 12 weeks
|
At the end of 12 weeks
|
|
Attentional Matrices Test
Time Frame: At the end of 12 weeks
|
At the end of 12 weeks
|
|
Prose recall test ( babcock)
Time Frame: At the end of 12 weeks
|
At the end of 12 weeks
|
|
Frontal Assessment battery (FAB)
Time Frame: At the end of 12 weeks
|
At the end of 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 7, 2024
Primary Completion (Actual)
May 15, 2024
Study Completion (Actual)
June 30, 2024
Study Registration Dates
First Submitted
October 29, 2024
First Submitted That Met QC Criteria
October 30, 2024
First Posted (Estimated)
November 1, 2024
Study Record Updates
Last Update Posted (Estimated)
November 1, 2024
Last Update Submitted That Met QC Criteria
October 30, 2024
Last Verified
October 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11487/2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment
-
Saglik Bilimleri UniversitesiAnkara UniversityRecruitingAmnestic Mild Cognitive Impairment | Amnestic Mild Cognitive DisorderTurkey
-
Masaryk UniversityRecruitingMild Cognitive Impairment (MCI) Amnestic | Lewy Body Disease With Mild Cognitive Impairment | Parkinson's Disease With Mild Cognitive ImpairmentCzechia
-
High Point UniversityWake Forest University Health Sciences; Hebrew SeniorLifeRecruitingMild Cognitive Impairment (MCI)United States
-
Azienda Ospedaliera SS. Antonio e Biagio e Cesare...Dr. Schär AG / SPARecruitingMild Cognitive Impairment (MCI)Italy
-
Xuanwu Hospital, BeijingWuhan University; Beijing Friendship Hospital; First Affiliated Hospital Xi'an... and other collaboratorsRecruitingAmnestic Mild Cognitive ImpairmentChina
-
Immunotec Inc.RecruitingMild Cognitive Impairment (MCI)Canada
-
Çankırı Karatekin UniversityCompletedMild Cognitive Impairment (MCI)Turkey (Türkiye)
-
University of AlbertaCompleted
-
Friedhelm HummelThe Novartis Foundation; Wyss Center for Bio and Neuroengineering; Clinique Romande... and other collaboratorsCompletedMild Cognitive Impairment (MCI)Switzerland
-
Jennifer BramenNational Institutes of Health (NIH); National Institute on Aging (NIA)TerminatedAmnestic Mild Cognitive ImpairmentUnited States
Clinical Trials on Whole Body Electromyostimulation
-
Federal University of Health Science of Porto AlegreLeonhardt Ventures LLCCompleted
-
University of Erlangen-Nürnberg Medical SchoolParacelsus Medical UniversityCompleted
-
Federal University of Health Science of Porto AlegreCompletedChronic Obstructive Pulmonary DiseaseBrazil
-
Charite University, Berlin, Germanymiha bodytec GmbHUnknown
-
Cairo UniversityActive, not recruiting
-
Federal University of Health Science of Porto AlegreNot yet recruiting
-
University of Erlangen-Nürnberg Medical SchoolUnknownLymphoma | Hematologic Diseases | Leukemia | Cancer | Myeloma | Cachexia; CancerGermany
-
Universidad Rey Juan CarlosNot yet recruitingPost COVID Syndrome | Long Covid | Long COVID Fatigue | Post COVID Syndrome Long Covid
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompletedCancer | Muscle Weakness | Weight Loss | Cancer Cachexia | Muscle LossGermany